NEUROCRINE BIOSCIENCES INC NBIX

Neurocrine Biosciences’ strongest current evidence is not a rumour or a chart flourish, but its filed first quarter numbers. In the 10-Q for the period ending 2026-03-31, the company reported $814.5M of revenue from contracts with customers, $193.4M of operating income, $197.9M of net income attributable to parent and diluted EPS of $1.91. That gives the daily file a real operating base rather than a loose biotech mood.

The company’s commercial centre in the supplied evidence is INGREZZA. Neurocrine’s 10-Q says its experience in marketing and selling pharmaceutical products began with INGREZZA’s approval in 2017, when it hired a sales force and built distribution and reimbursement capabilities. The same filing points to customer concentration by saying the table presents customers individually accounting for 10% or more of total gross product sales. That matters because the product story is not only science; it is also payer access, channel dependence and sales execution.

The balance sheet and cash flow rail are equally material. For the period ending 2026-03-31, SEC EDGAR filed financials show assets of $4.91B, liabilities of $1.50B and stockholders’ equity attributable to parent of $3.41B. Cash and cash equivalents stood at $266.5M, net cash provided by operating activities was $145.8M, payments to acquire property, plant and equipment were $9.1M, inventory net was $64.5M and the increase in inventories was $-4.3M. Diluted weighted average shares outstanding were 103.4M shares.

The latest named developments are filings, not a supplied price tape. The rail includes Form 4 filings dated 2026-06-09, 2026-06-08 and 2026-06-04, a Form 144 dated 2026-06-05, the SEC filing index, submissions JSON and companyfacts JSON. Because no chart route or price level is supplied, this report should not pretend to see candles, support, resistance or momentum. The market mechanism visible here is the official document trail: operating results, insider transaction filings, equity plan approval and acquisition disclosure.

On 2026-05-28, Neurocrine filed an 8-K stating that stockholders approved an amendment of the company’s 2025 Equity Incentive Plan at the 2026 Annual Meeting of Stockholders. That belongs in the same story as the Form 4 and Form 144 activity because management incentives and insider filing cadence are part of the current public record. The evidence does not say whether those filings are bullish, bearish or routine, so the clean reading is narrower: compensation structure and insider reporting are active parts of the present file.

The product and deal rail adds another concrete layer. A May 18, 2026 press release said Neurocrine completed its transaction involving an approved medicine for hyperphagia in adults and paediatric patients aged 4 years and older with Prader-Willi syndrome, and said the transaction was first announced on April 6, 2026 with a total equity value of $2.9B. The 10-Q also says Nxera may be entitled to potential future payments of up to $2.48B on event-based milestones and royalties on future net sales of any collaboration product. What remains unproven in this source pack is the next revenue contribution, integration progress and updated guidance.